Marilyn L Kwan1, Janise M Roh2, Cecile A Laurent2, Jean Lee2, Li Tang3, Dawn Hershman4, Lawrence H Kushi2, Song Yao3. 1. Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA. Marilyn.L.Kwan@kp.org. 2. Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA. 3. Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. 4. Department of Medicine and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, 10032, USA.
Abstract
PURPOSE: Breast cancer patients can switch hormonal therapy (HT) regimens due to treatment side effects or menopausal status change. We describe HT class switching from aromatase inhibitor (AI) to tamoxifen (TAM), and vice versa. METHODS: In a cohort of 3,265 women diagnosed with hormone-receptor-positive breast cancer at Kaiser Permanente Northern California from 2005 to 2013, we analyzed prescription records, switching reasons, and treatment adherence post-switch by chart review, through 31 December 2014. RESULTS: There were 290 women who switched from AI to TAM (AI switchers), including 130 (45%) switchers during the first year of treatment; and 446 women who switched from TAM to AI (TAM switchers), including 120 (27%) switchers within the first year. After the switch, 136 (47%) AI switchers and 260 (58%) TAM switchers finished or remained on the planned therapy; 69 (24%) AI switchers and 99 (22%) TAM switchers discontinued therapy. AI side effects (73%), specifically joint pain/arthralgia and bone health issues, were the most common reasons for switching from AI to TAM, whereas from TAM to AI, it was menopausal status change (42%). CONCLUSIONS: Study findings highlight the need for better ways to control patient symptoms from HT to prevent discontinuation, and thus ensure best prognosis.
PURPOSE:Breast cancerpatients can switch hormonal therapy (HT) regimens due to treatment side effects or menopausal status change. We describe HT class switching from aromatase inhibitor (AI) to tamoxifen (TAM), and vice versa. METHODS: In a cohort of 3,265 women diagnosed with hormone-receptor-positive breast cancer at Kaiser Permanente Northern California from 2005 to 2013, we analyzed prescription records, switching reasons, and treatment adherence post-switch by chart review, through 31 December 2014. RESULTS: There were 290 women who switched from AI to TAM (AI switchers), including 130 (45%) switchers during the first year of treatment; and 446 women who switched from TAM to AI (TAM switchers), including 120 (27%) switchers within the first year. After the switch, 136 (47%) AI switchers and 260 (58%) TAM switchers finished or remained on the planned therapy; 69 (24%) AI switchers and 99 (22%) TAM switchers discontinued therapy. AI side effects (73%), specifically joint pain/arthralgia and bone health issues, were the most common reasons for switching from AI to TAM, whereas from TAM to AI, it was menopausal status change (42%). CONCLUSIONS: Study findings highlight the need for better ways to control patient symptoms from HT to prevent discontinuation, and thus ensure best prognosis.
Entities:
Keywords:
Aromatase inhibitors; Breast cancer; Cancer survivor; Cohort study; Hormonal therapy; Tamoxifen
Authors: Uwe Güth; Mary Elizabeth Myrick; Andreas Schötzau; Nerbil Kilic; Seraina Margaretha Schmid Journal: Breast Cancer Res Treat Date: 2011-07-13 Impact factor: 4.872
Authors: Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: Dawn L Hershman; Lawrence H Kushi; Theresa Shao; Donna Buono; Aaron Kershenbaum; Wei-Yann Tsai; Louis Fehrenbacher; Scarlett Lin Gomez; Sunita Miles; Alfred I Neugut Journal: J Clin Oncol Date: 2010-06-28 Impact factor: 44.544
Authors: Dawn L Hershman; Theresa Shao; Lawrence H Kushi; Donna Buono; Wei Yann Tsai; Louis Fehrenbacher; Marilyn Kwan; Scarlett Lin Gomez; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2010-08-28 Impact factor: 4.872
Authors: Marilyn L Kwan; Christine B Ambrosone; Marion M Lee; Janice Barlow; Sarah E Krathwohl; Isaac Joshua Ergas; Christine H Ashley; Julie R Bittner; Jeanne Darbinian; Keren Stronach; Bette J Caan; Warren Davis; Susan E Kutner; Charles P Quesenberry; Carol P Somkin; Barbara Sternfeld; John K Wiencke; Shichun Zheng; Lawrence H Kushi Journal: Cancer Causes Control Date: 2008-05-14 Impact factor: 2.506
Authors: Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto Journal: J Clin Oncol Date: 2009-11-30 Impact factor: 44.544
Authors: Alison T Stopeck; Patricia A Thompson; Jessica A Martinez; Betsy C Wertheim; Denise J Roe; Pavani Chalasani; Jules Cohen; Lea Baer; H-H Sherry Chow Journal: Breast Cancer Res Treat Date: 2022-01-18 Impact factor: 4.872
Authors: Kate E Roberts; India T Adsett; Kirsty Rickett; Sophie M Conroy; Mark D Chatfield; Natasha E Woodward Journal: Cochrane Database Syst Rev Date: 2022-01-10
Authors: Marina M Reeves; Caroline O Terranova; Elisabeth A H Winkler; Nicole McCarthy; Ingrid J Hickman; Robert S Ware; Sheleigh P Lawler; Elizabeth G Eakin; Wendy Demark-Wahnefried Journal: Nutrients Date: 2021-11-15 Impact factor: 5.717
Authors: Marcus Schmidt; Hans Lenhard; Arnd Hoenig; Yvette Zimmerman; Jan Krijgh; Monique Jansen; Herjan J T Coelingh Bennink Journal: J Cancer Res Clin Oncol Date: 2020-11-26 Impact factor: 4.553
Authors: Tara Hyder; Christopher C Marino; Sasha Ahmad; Azadeh Nasrazadani; Adam M Brufsky Journal: Front Endocrinol (Lausanne) Date: 2021-07-27 Impact factor: 5.555